2 Top Biotech Stocks to Buy Right Now
These companies could crush the broader markets this year.
Acceleron Pharma
XLRN
XLRN
$87.12
-$1.07
-1.2%
Price as of February 26, 2020, 3:29 p.m. EST
View Interactive XLRN Charts
CONTROLADORA VUELA SPON ADR REPR 10 CPOS
Interactive Chart
News & Analysis: Acceleron Pharma
Why Acceleron Pharma Stock Bolted Higher in January
Acceleron's shares skyrocketed last month after its experimental PAH drug hit the mark in a midstage trial.
Is Acceleron Pharma Stock a Buy?
The stock's price surged following a clinical trial success, but should investors now temper their enthusiasm?
Here's Why Shares of Acceleron Pharma Rocketed Higher Today
A successful midstage clinical trial has investors giddy, but the devil will be in the details.
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
The new drug treats high blood pressure in the lungs.
Here's Why Bristol-Myers Squibb Jumped 12.7% in December
Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.
Acceleron Pharma Inc (XLRN) Q3 2019 Earnings Call Transcript
XLRN earnings call for the period ending .
Acceleron's Q3 Results Focus Squarely on Its Celgene Collaboration
The biotech's Q3 results and future fortunes hinge on approvals for the blood-disease drug it licensed to Celgene.
Here’s Why Acceleron Pharma Stock Fell 12% in September
The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
Don't Dismiss Acceleron Despite Its Recent Clinical Setback
The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel.
